MorphoSys AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MOR research report →
Companywww.morphosys.com
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2.
- CEO
- Arkadius Pichota
- IPO
- 2018
- Employees
- 464
- HQ
- Planegg, DE
Price Chart
Valuation
- Market Cap
- $2.86B
- P/E
- -11.79
- P/S
- 10.31
- P/B
- 45.62
- EV/EBITDA
- -30.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 75.51%
- Op Margin
- -105.96%
- Net Margin
- -79.63%
- ROE
- -183.80%
- ROIC
- -14.13%
Growth & Income
- Revenue
- $238.28M · -14.37%
- Net Income
- $-189,734,199 · -25.60%
- EPS
- $-1.38 · -25.11%
- Op Income
- $-252,475,802
- FCF YoY
- 21.79%
Performance & Tape
- 52W High
- $19.50
- 52W Low
- $4.18
- 50D MA
- $18.46
- 200D MA
- $14.73
- Beta
- 0.66
- Avg Volume
- 47.07K
Get TickerSpark's AI analysis on MOR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MOR Coverage
We haven't published any research on MOR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MOR Report →